Short answer
Edwards Lifesciences (EW) filed its fiscal 2024 10-K annual report with the SEC on Feb 28, 2025. It reported revenue of $5.4B (−9.4% year over year) and net income of $4.2B.
- Top risk flagged: No specific, timely regulatory or legal risk identified in the text
FY2024 key financial metrics · XBRL
- Revenue
- $5.4B
- −9.4% YoY
- Net income
- $4.2B
- +197.7% YoY
- Operating margin
- 25.3%
- −0.2 pp YoY
- Gross margin
- 79.5%
- +2.4 pp YoY
- EPS (diluted)
- $6.97
- +203.0% YoY
- ROE
- 41.8%
- +20.7 pp YoY
- Operating cash flow
- $542M
- −39.5% YoY
Source: XBRL data from the Edwards Lifesciences (EW) FY2024 10-K on SEC EDGAR. USD.
Edwards Lifesciences FY2024 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Development, manufacturing, and marketing of structural heart therapies and medical technologies globally
- New emphasis on divestiture of Critical Care product group completed Sept 2024 to refine portfolio focus
- Strategic shift towards managing acquisitions integration risks and divesting underperforming or non-core assets
- Operating globally with risks from currency fluctuations; no specific employee or R&D spend changes disclosed
- Noteworthy operational complexity and financial risk from transitional arrangements after Critical Care divestiture
Management Discussion & Analysis
- Revenue $5.44B, up $429.5M (8.6%) YoY in 2024, driven by TAVR and TMTT growth
- Gross profit margin declined due to foreign currency impact; exact margin % figures not disclosed
- Best segment: United States $3.21B (+$258.1M, +8.8%); worst segment: Japan $340M (-$11M, -3.1%)
- Sold Critical Care for $4.2B; invested 19% of net sales in R&D; dividend and buyback data not provided
- Management focuses on innovation, clinical trials, and structural heart disease treatment; expects growth via new product launches and acquisitions
Risk Factors
- No specific, timely regulatory or legal risk identified in the text
- No geopolitical or macroeconomic threat with concrete exposure details mentioned
- Cybersecurity risk managed by Chief Information Security Officer with regular Board updates on detection and response capabilities
- No direct competitor or market disruption risk detailed in the provided section
- Enterprise-wide risk management overseen by senior leadership with dedicated councils but no financial or structural risk specifics disclosed
Generated from the filing text; verify against the original. How to read a 10-K
Other Edwards Lifesciences annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.